Cargando…
Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma
BACKGROUND: Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells appears to be a promising immunotherapeutic strategy. CAR combines the specificity of antibody and cytotoxicity of cytotoxic T lymphocytes, enhancing T cells’ ability to specifically target antigens and to effectively...
Autores principales: | Shen, Chan-Juan, Yang, Yu-Xiu, Han, Ethan Q, Cao, Na, Wang, Yun-Fei, Wang, Yi, Zhao, Ying-Ying, Zhao, Li-Ming, Cui, Jian, Gupta, Puja, Wong, Albert J, Han, Shuang-Yin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658918/ https://www.ncbi.nlm.nih.gov/pubmed/23656794 http://dx.doi.org/10.1186/1756-8722-6-33 |
Ejemplares similares
-
Development of an EGFRvIII specific recombinant antibody
por: Gupta, Puja, et al.
Publicado: (2010) -
Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma
por: Sahin, Ayguen, et al.
Publicado: (2018) -
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016) -
Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015) -
Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
por: Ren, Pei-pei, et al.
Publicado: (2017)